Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without ...
Roche Holding AG’s experimental multiple sclerosis pill roughly halved the number of disease relapses in two key late-stage ...
The experimental drug fenebrutinib worked better than Aubagio, an approved therapy, for reducing relapse rates in MS, new ...
The Phase II trial enrolled 129 participants, of whom 94% had relapsing remitting multiple sclerosis, and 6% had secondary ...
Late-stage data shows strong relapse reduction versus teriflunomide alongside an imbalance in deaths with no clear pattern identified ...
By Marleen Kaesebier and Patricia Weiss ZURICH, April 22 (Reuters) - Swiss drugmaker Roche on Wednesday said it was ...
These results underscore that fenebrutinib has potential as a high-efficacy oral treatment for RMS. Its unique mode of action may offer a differentiated profile by targeting dual drivers of MS within ...
A new MS blood test from Roche has received EU approval and may help track disease activity by measuring nerve damage linked ...
October 24, 2011 (Amsterdam, the Netherlands) — The full results of a phase 3 trial directly comparing alemtuzumab (Lemtrada, Genzyme) with interferon-beta-1a (Rebif, EMD Serono/Pfizer) show a ...
Multiple sclerosis MS book and prescription and pen. A blood test might predict relapses in MS Neurofilament light chain levels spike in MS patients’ blood before a relapse However, the prediction ...
For many years, women with multiple sclerosis (MS) were advised not to become pregnant because of concerns about relapses after childbirth. But research now shows that pregnancy doesn't make MS worse, ...
Antje Ronneberger says symptoms like balance problems means strangers wrongly assume she is drunk.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results